Management of hepatitis B in developing countries
- PMID: 22216369
- PMCID: PMC3246547
- DOI: 10.4254/wjh.v3.i12.292
Management of hepatitis B in developing countries
Abstract
Hepatitis B is one of the leading causes of chronic hepatitis in developing countries, with 5% to 15% of the population carrying virus. The high prevalence is due to failure to adopt appropriate measure to confine the spread of infection. Most hepatitis B patients present with advanced diseases. Although perinatal transmission is believed to be an important mode, most infections in the developing world occur in childhood and early adulthood. Factors in developing countries associated with the progression of chronic hepatitis B (CHB) include co-infections with human immunodeficiency virus, delta hepatitis virus, hepatitis C virus, alcohol intake and aflatoxin. Treatment protocols extrapolated from developed countries may need modifications according to the resources available. There is some controversy as to when to start treatment, with what medication and for how long? There is now enough evidence to support that hepatitis B patients should be considered for treatment if they show persistently elevated abnormal aminotransferase levels in the last 6 mo, checked on at least three separate occasions, and a serum hepatitis B virus DNA level of > 2000 IU/mL. Therapeutic agents that were approved by Pure Food and Drug Administration are now available in many developing countries. These include standard interferon (INF)-α, pegylated INF-α, lamivudine, adefovir, entecavir and telbivudine. Drug resistance has emerged as a major challenge in the management of patients with CHB. The role of the universal vaccination program for effective control of hepatitis B cannot be emphasized enough.
Keywords: Developing countries; Hepatitis B; Hepatitis B surface antigen; Hepatitis B virus DNA; Management; Vaccination.
Figures


Similar articles
-
Treatment of chronic hepatitis B: case selection and duration of therapy.J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. doi: 10.1046/j.1440-1746.2002.02767.x. J Gastroenterol Hepatol. 2002. PMID: 11982721 Review.
-
Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.Drugs Today (Barc). 2007 Apr;43(4):201-20. doi: 10.1358/dot.2007.43.4.1037479. Drugs Today (Barc). 2007. PMID: 17460784 Review.
-
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.Clin Gastroenterol Hepatol. 2015 Nov;13(12):2071-87.e16. doi: 10.1016/j.cgh.2015.07.007. Epub 2015 Jul 15. Clin Gastroenterol Hepatol. 2015. PMID: 26188135 Review.
-
Management of hepatitis B: Pakistan Society for the Study of Liver Diseases (PSSLD) practice guidelines.J Coll Physicians Surg Pak. 2010 Mar;20(3):198-201. J Coll Physicians Surg Pak. 2010. PMID: 20392385
-
Management of chronic hepatitis B.Evid Rep Technol Assess (Full Rep). 2008 Oct;(174):1-671. Evid Rep Technol Assess (Full Rep). 2008. PMID: 19408969 Free PMC article. Review.
Cited by
-
Liver diseases in developing countries.World J Hepatol. 2012 Mar 27;4(3):66-7. doi: 10.4254/wjh.v4.i3.66. World J Hepatol. 2012. PMID: 22489257 Free PMC article.
-
Social Determinants of Stigma and Discrimination in Vietnamese Patients with Chronic Hepatitis B.Int J Environ Res Public Health. 2019 Jan 31;16(3):398. doi: 10.3390/ijerph16030398. Int J Environ Res Public Health. 2019. PMID: 30708943 Free PMC article.
-
Single nucleotide polymorphisms in ZNF208 are associated with increased risk for HBV in Chinese people.Oncotarget. 2017 Jul 28;8(68):112451-112459. doi: 10.18632/oncotarget.19669. eCollection 2017 Dec 22. Oncotarget. 2017. PMID: 29348838 Free PMC article.
-
Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections.Clin Rev Allergy Immunol. 2016 Feb;50(1):41-54. doi: 10.1007/s12016-014-8465-4. Clin Rev Allergy Immunol. 2016. PMID: 25480494 Review.
-
Prevalence of Hepatitis B Virus Infection and Factors Associated with Hepatitis B Virus Infection Among Pregnant Women Presented to Antenatal Care Clinics at Adigrat General Hospital in Northern Ethiopia.Int J Womens Health. 2021 Jan 22;13:119-127. doi: 10.2147/IJWH.S280806. eCollection 2021. Int J Womens Health. 2021. PMID: 33519245 Free PMC article.
References
-
- Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745. - PubMed
-
- Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13 Suppl 1:S47–S49. - PubMed
-
- Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16. - PubMed
-
- McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis. 2004;24 Suppl 1:17–21. - PubMed
-
- Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992–1000. - PubMed
LinkOut - more resources
Full Text Sources